Spotlight Back On Indian Rotavirus Vaccine Controversy
Executive Summary
A public interest litigation (PIL) has sought to revive efforts to access segregated trial data from an indigenous oral rotavirus vaccine (Rotavac) in India amid concerns that it might be associated with a higher risk of intussusception in certain pockets of the country. And in a further dimension, an expert panel recently brought up a "representation" on the inclusion of intussusception in the vaccine's package insert.
You may also be interested in...
Indian Court Dismisses "Misconceived" PIL On Rotavirus Vaccine
An Indian court has dismissed a petition seeking complete trial data pertaining to an indigenous oral rotavirus vaccine (Rotavac) developed through a unique public-private partnership, noting that it is "misconceived" and "motivated with private interest".
India's rotavirus vaccine row: show me the data
A public interest litigation (PIL) has brought to the fore a simmering controversy over alleged safety signals concerning an indigenous oral rotavirus vaccine (Rotavac) developed through a unique public-private partnership in India.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.